Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

liraglitude

- PMLiVE

Sanofi and T1D Exchange collaborate to understand needs of children living with diabetes

Aims to deliver recommendations for better disease management and patient outcomes

- PMLiVE

EU approval for AZ/BMS’ first-in-class diabetes drug Forxiga

First SGLT2 inhibitor to be approved for marketing anywhere in the world

- PMLiVE

WHO launches framework to monitor non-communicable diseases

Will measure success of efforts to reduce rates of cancer, diabetes, lung conditions and heart disease

- PMLiVE

Merck & Co stops development of Januvia, atorvastatin combo

Company spokesperson claims decision is for “business reasons”

- PMLiVE

Lilly launches diabetes partnership programme in South Africa

Partners with Project Hope and Donald Woods Foundation

- PMLiVE

Novo Nordisk’s new insulin moves closer to US approval

Follows recommendation in Europe

Sanofi’s Christopher Viehbacher to take the reins at EFPIA

Will serve as European pharma body's president from next June

- PMLiVE

Novo Nordisk posts ‘robust’ gains in sales and earnings

Diabetes drug Victoza and insulin analogue portfolio see strong growth

- PMLiVE

Boehringer-Lilly win expanded European licence for Trajenta

Type 2 diabetes drug approved as add-on to insulin in adults

- PMLiVE

Sanofi nearing end of patent cliff, says Viehbacher

Higher third-quarter revenues see pharma company raise forecasts for 2012

Genzyme enters $22.5m RNAi deal with Alnylam in Asia

Programme targets condition affecting heart and nervous system

- PMLiVE

Vivus fails to get European backing for obesity treatment Qsiva

EMA raises concerns about drug’s cardiovascular safety

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links